Challenges and opportunities in nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH) has emerged as the leading cause of chronic liver disease worldwide and is rapidly increasing in prevalence due to the obesity epidemic. There are currently no Food and Drug Administration (FDA) approved drugs to treat NASH, and therefore a critical need exists fo...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
De Gruyter
2022-08-01
|
| Colección: | Medical Review |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1515/mr-2022-0024 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|